國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Regulation of cancer immune checkpoi...

SpringerLink (Online service)

Regulation of cancer immune checkpointsmolecular and cellular mechanisms and therapy /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Regulation of cancer immune checkpointsedited by Jie Xu.
其他題名:	molecular and cellular mechanisms and therapy /
其他作者:	Xu, Jie.
出版者:	Singapore :Springer Singapore :2020.
面頁冊數:	x, 653 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	CancerImmunological aspects.
電子資源:	https://doi.org/10.1007/978-981-15-3266-5
ISBN:	9789811532665$q(electronic bk.)

Regulation of cancer immune checkpointsmolecular and cellular mechanisms and therapy /
Regulation of cancer immune checkpointsmolecular and cellular mechanisms and therapy /[electronic resource] :edited by Jie Xu. - Singapore :Springer Singapore :2020. - x, 653 p. :ill., digital ;24 cm. - Advances in experimental medicine and biology,v.12480065-2598 ;. - Advances in experimental medicine and biology ;946..

Introduction -- Molecular and cellular functions of CTLA-4 pathway -- Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond -- Discovery of new immune checkpoints: family grows up -- Mechanisms of resistance to checkpoint blockade therapy -- Molecular events behind adverse effects -- Rational discovery of response biomarkers -- Spatiotemporal changes in checkpoint molecule expression -- Functions of checkpoint molecules beyond immune evasion -- Genetic alterations and checkpoint expression -- Regulations on messenger RNA: wires and nodes -- Folded or degraded in endoplasmic reticulum -- Mono- and poly-ubiquitination: tags for fates -- Lysosome as the black hole for checkpoint molecules -- Phosphorylation: a fast switch for checkpoint signalling -- Palmitoylation as a signal for delivery -- Checkpoints under traffic control: from and to organelles -- Exosome and secretion: action on? -- Macromolecules and antibody-based drugs -- Mechanisms inspired targeting peptides -- Small molecular inhibitors -- Therapeutic development of immune checkpoint blockers -- Concluding remarks.

This book systematically reviews the most important findings on cancer immune checkpoints, sharing essential insights into this rapidly evolving yet largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA (PD-1L)/VSIG3, CD47/SIRPA, APOE/LILRB4, TIGIT, and many others. Despite these strides, most patients do not show lasting remission, and some cancers have been completely resistant to the therapy. The potentially lethal adverse effects of checkpoint blockade represent another major challenge, the mechanisms of which remain poorly understood. Compared to the cancer signaling pathways, such as p53 and Ras, mechanistic studies on immune checkpoint pathways are still in their infancy. To improve the responses to checkpoint blockade therapy and limit the adverse effects, it is essential to understand the molecular regulation of checkpoint molecules in both malignant and healthy cells/tissues. This book begins with an introduction to immune checkpoint therapy and its challenges, and subsequently describes the regulation of checkpoints at different levels. In closing, it discusses recent therapeutic developments based on mechanistic findings, and outlines goals for future translational studies. The book offers a valuable resource for researchers in the cancer immunotherapy field, helping to form a roadmap for checkpoint regulation and develop safer and more effective immunotherapies.

ISBN: 9789811532665$q(electronic bk.)

Standard No.: 10.1007/978-981-15-3266-5doiSubjects--Topical Terms:

484440
Cancer
--Immunological aspects.

LC Class. No.: RC268.3 / .R448 2020

Dewey Class. No.: 616.994079

Regulation of cancer immune checkpointsmolecular and cellular mechanisms and therapy /
LDR:03839nmm a2200337 a 4500 001 572322
003 DE-He213
005 20200727134033.0
006 m d
007 cr nn 008maaau
008 200925s2020 si s 0 eng d
020 $a 9789811532665$q(electronic bk.)
020 $a 9789811532658$q(paper)
024 7 $a 10.1007/978-981-15-3266-5 $2 doi
035 $a 978-981-15-3266-5
040 $a GP $c GP
041 0 $a eng
050 4 $a RC268.3 $b .R448 2020
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994079 $2 23
090 $a RC268.3 $b .R344 2020
245 0 0 $a Regulation of cancer immune checkpoints $h [electronic resource] : $b molecular and cellular mechanisms and therapy / $c edited by Jie Xu.
260 $a Singapore : $b Springer Singapore : $b Imprint: Springer, $c 2020.
300 $a x, 653 p. : $b ill., digital ; $c 24 cm.
490 1 $a Advances in experimental medicine and biology, $x 0065-2598 ; $v v.1248
505 0 $a Introduction -- Molecular and cellular functions of CTLA-4 pathway -- Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond -- Discovery of new immune checkpoints: family grows up -- Mechanisms of resistance to checkpoint blockade therapy -- Molecular events behind adverse effects -- Rational discovery of response biomarkers -- Spatiotemporal changes in checkpoint molecule expression -- Functions of checkpoint molecules beyond immune evasion -- Genetic alterations and checkpoint expression -- Regulations on messenger RNA: wires and nodes -- Folded or degraded in endoplasmic reticulum -- Mono- and poly-ubiquitination: tags for fates -- Lysosome as the black hole for checkpoint molecules -- Phosphorylation: a fast switch for checkpoint signalling -- Palmitoylation as a signal for delivery -- Checkpoints under traffic control: from and to organelles -- Exosome and secretion: action on? -- Macromolecules and antibody-based drugs -- Mechanisms inspired targeting peptides -- Small molecular inhibitors -- Therapeutic development of immune checkpoint blockers -- Concluding remarks.
520 $a This book systematically reviews the most important findings on cancer immune checkpoints, sharing essential insights into this rapidly evolving yet largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA (PD-1L)/VSIG3, CD47/SIRPA, APOE/LILRB4, TIGIT, and many others. Despite these strides, most patients do not show lasting remission, and some cancers have been completely resistant to the therapy. The potentially lethal adverse effects of checkpoint blockade represent another major challenge, the mechanisms of which remain poorly understood. Compared to the cancer signaling pathways, such as p53 and Ras, mechanistic studies on immune checkpoint pathways are still in their infancy. To improve the responses to checkpoint blockade therapy and limit the adverse effects, it is essential to understand the molecular regulation of checkpoint molecules in both malignant and healthy cells/tissues. This book begins with an introduction to immune checkpoint therapy and its challenges, and subsequently describes the regulation of checkpoints at different levels. In closing, it discusses recent therapeutic developments based on mechanistic findings, and outlines goals for future translational studies. The book offers a valuable resource for researchers in the cancer immunotherapy field, helping to form a roadmap for checkpoint regulation and develop safer and more effective immunotherapies.
650 0 $a Cancer $x Immunological aspects. $3 484440
650 1 4 $a Cancer Research. $3 273660
650 2 4 $a Immunology. $3 189152
650 2 4 $a Molecular Medicine. $3 273932
700 1 $a Xu, Jie. $3 859328
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Advances in experimental medicine and biology ; $v 946. $3 557559
856 4 0 $u https://doi.org/10.1007/978-981-15-3266-5
950 $a Biomedical and Life Sciences (Springer-11642)